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Abstract
Introduction: In cancer cells, elevated transcription factor-related Brn-3a regulator isolated from brain cDNA (Brn-
3b) transcription factor enhances proliferation in vitro and increases tumour growth in vivo whilst conferring drug
resistance and migratory potential, whereas reducing Brn-3b slows growth both in vitro and in vivo. Brn-3b
regulates distinct groups of key target genes that control cell growth and behaviour. Brn-3b is elevated in >65% of
breast cancer biopsies, but mechanisms controlling its expression in these cells are not known.
Methods: Bioinformatics analysis was used to identify the regulatory promoter region and map transcription start
site as well as transcription factor binding sites. Polymerase chain reaction (PCR) cloning was used to generate
promoter constructs for reporter assays. Chromatin immunoprecipitation and site-directed mutagenesis were used
to confirm the transcription start site and autoregulation. MCF-7 and Cos-7 breast cancer cells were used. Cells
grown in culture were transfected with Brn-3b promoter and treated with growth factors or estradiol to test for
effects on promoter activity. Quantitative reverse transcriptase PCR assays and immunoblotting were used to
confirm changes in gene and protein expression.
Results: We cloned the Brn-3b promoter, mapped the transcription start site and showed stimulation by estradiol
and growth factors, nerve growth factor and epidermal growth factor, which are implicated in breast cancer
initiation and/or progression. The effects of growth factors are mediated through the mitogen-activated protein
kinase pathway, whereas hormone effects act via oestrogen receptor a (ERa). Brn-3b also autoregulates its
expression and cooperates with ERa to further enhance levels.
Conclusions: Key regulators of growth in cancer cells, for example, oestrogens and growth factors, can stimulate
Brn-3b expression, and autoregulation also contributes to increasing Brn-3b in breast cancers. Since increasing Brn-
3b profoundly enhances growth in these cells, understanding how Brn-3b is increased in breast cancers will help
to identify strategies for reducing its expression and thus its effects on target genes, thereby reversing its effects in
breast cancer cells.
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Introduction
The class 4 POU (Pit-Oct-Unc) transcription factor-2-
related to Brn-3 (POU4F2/Brn-3b), is referred to as
Brn-3b because of homology in the DNA binding
domain to the related Brn-3a transcription factor. Brn-
3b is highly expressed in a significant proportion (>
65%) of breast tumour biopsies analyzed [1]. Over-
expression of Brn-3b in cancer cells is strongly asso-
ciated with increased proliferation, in vitro, and
enhanced tumour growth, in-vivo, whereas reducing
Brn-3b (by antisense) decreases proliferation in-vitro
and results in smaller, slower growing tumours in-vivo
[2,3]. Brn-3b also confers resistance to growth inhibitory
or apoptosis inducing chemotherapeutic drugs but also
increases migratory potential of cancer cells [2]. Recent
studies also showed that Brn3b is increased in doxorubi-
cin resistant breast cancer cells (R Fujita and V Budh-
ram-Mahadeo, unpublished data).
As a transcription factor, Brn-3b regulates the expres-
sion of critical genes that control different cellular pro-
cesses. For example, increased proliferation by Brn-3b
may be associated with its ability to transactivate the
promoters of genes required for cell cycle progression
such as cyclin-dependent kinase 4 (CDK4) [4] and its
regulatory partner cyclin D1 [5], which are required,
whilst repressing breast cancer susceptibility gene 1
(BRCA1) [6], which is associated with cell cycle arrest in
breast cancer cells. Invasiveness and drug resistance
associated with Brn-3b in cancer cells are linked with its
ability to transactivate genes such as the small heat
shock protein 27 (HSP27) [7] whilst repressing promo-
ters of genes encoding adhesion molecules, for example,
g-catenin/plakoglobin [8].
However, whilst the effects of increased Brn-3b in
cancer cells have been characterised and many of its tar-
get genes have been studied, we do not know which fac-
tors contribute to the elevated Brn-3b mRNA and
protein levels observed in breast cancer. In this study,
we have cloned and analysed the regulatory region that
controls Brn-3b gene expression in MCF-7 breast cancer
cells. The results presented herein identify a proximal
promoter present in the 5’ sequences upstream of the
Brn-3b gene which drives expression in MCF-7 cells.
This promoter is transactivated by the growth factors
nerve growth factor (NGF) and epidermal growth factor
(EGF) and the hormone estradiol, all of which are
known to promote the proliferation and/or survival of
breast cancer cells. NGF and EGF increase promoter
activity by signalling through the p42/p44-(ERK) mito-
gen-activated protein kinase (MAPK) pathway, whereas
the effects of oestrogen are mediated via oestrogen
receptor a (ERa) but not oestrogen receptor b (ERb).
We also show autoregulation by Brn-3b to increase its
own expression. These findings suggest that increased
transcription of Brn-3b in breast cancer cells is stimu-
lated by growth factors and hormones that enhance pro-
liferation and propagate through autoregulation.
Materials and methods
Materials
General laboratory reagents were purchased from Merck
(Nottingham, UK) and Sigma (Dorset, UK) unless other-
wise stated. Primary antibodies were used at dilutions of
1: 1000-1500 and included Brn-3b-rabbit pAb (Abcam-
Cambridge, UK); Brn-3b-goat pAb (Santa Cruz Biotech-
nology Inc, USA); actin - goat pAb (I-19, Santa Cruz
Biotechnology). HRP-conjugated secondary Ab from
Dako (Cambridgeshire, UK) was used for immunoblot-
ting 1:2000). Estradiol (E4389), cyclic adenosine mono-
phosphate (cAMP), phorbol 12,13-dibutyrate (PDBu)
and 4-hydroxytamoxifen (tamoxifen) were from Sigma
(Dorset, UK); epidermal growth factor (EGF), transform-
ing growth factor-b (TGF-b); insulin-like growth-1 (IGF
1) and nerve growth factor (NGF) were from Roche
Diagnostics GmbH (Welwyn Garden City, Hertfordshire,
UK). Signalling pathway inhibitors PD-98059 (MEK),
SB-203580 kinase (p38), Genistein (tyrosine kinase), and
Wortmannin (PI3-kinase) were from Calbiochem (Not-
tingham, UK). The MCF7 breast cancer cell line was
obtained from ATCC. Expression vectors, Brn-3b(l);
Brn-3b(s); ER were previously described [9]. Dominant
negative and constitutively active MEK expression vec-
tors were kind gift from D.S. Latchman[10].
In silico analysis of Brn-3b promoter
Homo sapiens chromosome 4 contig was analysed using
the Basic Local Alignment Search Tool, or BLAST [11],
to identify a region containing the Brn-3b gene consist-
ing of approximately 10 kb sequence (in bacterial artifi-
cial chromosome clone AC093887). Further analysis
using Bioinformatics and Molecular Analysis Section
(BIMAS) ProScan software [12] was used to identify
putative promoter sequences in this region of DNA.
The VISTA Genome Browser [11] was used to generate
homology plots, whereas analysis using Genomatix
TRANSFAC software analysis (Genomatix, Munich,
Germany) identified binding sites for transcription fac-
tors in the putative promoter sequences.
Brn-3b reporter constructs
Brn-3b reporter constructs were generated so that the
regulatory promoter region drove expression of a firefly
luciferase reporter gene in the pGL2 plasmid. The initial
Brn-3b reporter construct was generated by amplifying
~1,400 bp regions upstream of the Brn-3b gene
sequence and incorporating part of exon 1 (Figure 1b).
The resultant construct was designated BstX1/Stu1/
Xho1 (BSX) because it included sequences that can be
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isolated using restriction BstX1, Xho1 site (exon 1) and
Stu1 site and were used for diagnostic digestion. The
BSX exon-intron-exon (BSXEIE) construct was subse-
quently generated by cloning the gene encoding
sequence (exon 1, intron and exon 2) upstream of this
putative regulatory region, thus allowing Brn-3b promo-
ter to drive its own gene expression.
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation (ChIP) assay was car-
ried out as described by Lee et al. [7]. In studies to identify
the transcription start sites, anti-TATA box binding protein
(anti-TBP) Ab (Abcam) was used to immunoprecipitate
regions of promoter bound by TBP in the transcription
initiation complex. Later studies to confirm Brn-3b binding
Figure 1 Identification and cloning of transcription start site in transcription factor-related Brn-3a regulator isolated from brain cDNA
(Brn-3b) promoter. (a) Homology plots (VISTA Genome Browser) showing regions of similarity in Brn-3b gene and 5’ upstream sequences
between human (top) and dog, horse and mouse (bottom) genome sequences. Regions of homology are indicated by peaks and grey shading,
and positions of Brn-3b exons and intronic sequences are shown. (b) Schematic showing cloned BstX1 (B)/Stu1 (S)/Xho1 (X) (BSX) construct
containing putative Brn-3b promoter and regulatory sequences or the BSX exon-intron-exon (BSXEIE) expression construct containing the
promoter, regulatory and coding sequences, which were used for subsequent studies. Promoter and regulatory sequences are shown in grey-
striped area. 5’ noncoding sequences at the beginning of exon 1 are indicated by the black bar. The white stripe at the start of exon 2
represents unique sequences that are present in Brn-3b(s) transcripts, but not in Brn-3b(l) transcripts. The positions of restriction enzyme sites
BstX1 (B), Stu1 (S) and Xho1 (X) used for cloning are also shown. (c) Luciferase activity of Brn-3b reporter constructs following transfection into
MCF-7 cells is compared with baseline luciferase activity of the empty reporter vector. Values, shown as relative luciferase units (RLU),, were
equalised with Renilla internal control (d) Schematic showing positions of putative start sites identified by in silico analysis. Initiator element and
proximal TATA sequences are shown relative to ATG in exon 1, and putative intronic TATA sequences are indicated. Half-arrows show relative
positions of primers used for polymerase chain reaction (PCR) assay following chromatin immunoprecipitation (ChIP) assay with a-TATA box
binding protein (a-TBP) antibody (Ab) to analyse TBP binding to the different sites. (e) PCR products obtained when ChIP DNA (obtained with
a-TBP Ab or secondary control Ab) was used for amplification with primers that flanked the upstream initiator elements (-1,048 bp) (A),
-278TATA (B) or the intronic TA sequences (C). Primers for sequences within exon 2 (> 1 kb from ATG) were used for amplification in the
negative control (D). Positive controls represent PCR products derived by using primers that amplified the known start site of the glyceraldehyde
3-phosphate dehydrogenase (GAPDH) gene using a-TBP or control ChIP DNA (E). Input represents amplification using one-tenth of DNA isolated
before performing the ChIP assay. Right column (labeled 2nd Ab) shows the products obtained following amplification of control ChIP Ab (a-
rabbit secondary Ab) using the indicated primers.
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in its own promoter was done using antigoat Brn-3b Ab
(Santa Cruz Biotechnology) to immunoprecipitate Brn-3b
bound to chromatin in intact cells. Negative control ChIP
assay was performed using antibody to glyceraldehyde 3-
phosphate dehydrogenase (anti-GAPDH) (Abcam) or sec-
ondary Ab (Dako) only. The shear size of DNA following
ChIP assay and sonication was ~200 to 600 bp as deter-
mined for agarose gel electrophoresis. The PCR assay for
the transcriptional start site was performed on ChIP DNA
using primers designed to amplify different regions of the
putative Brn-3b promoter as follows: Upstream initiator:
forward 5’-CTTGGGCCGCAACTTTATT-3’ and reverse
5’-TACCTAAGGACCAGCCTCCA-3’; -278TATA: for-
ward 5’-CGGGGAGAGGGGAGTATAAC-3’ and reverse
5’-GATGCCTGACTCCGCTTG-3’; intronic TA: forward
5’-TTGACAGCCCCCTTTATCTG-3’ and reverse 5’-AGG-
CAACATCCCAGGTCATA-3’; and negative control
primers which amplified the exon 2 sequence:
forward 5’-ACCATGAACCCCATGCAC-3’ and reverse 5’-
CTTGATGCCTCGCTGCTT-3’. The distance between the
intronic site and the exonic sequences amplified was ~1 kb.
As a positive control, the following primers were used to
amplify the GAPDH promoter start site: forward 5’-TGAG-
CAGACCGGTGTCAC-3’ and reverse 5’-AGGACTTTGG-
GAACGACTGA-3’. Primers used to amplify the promoter
region containing the Brn-3b site were as follows: forward
5’-GCCCCTTCTTCCTTTGATTG-3’ and reverse 5’-ACA-
CACACACGCTCCTCTTG-3’. Standard conditions for
PCR amplification included 2.5 mM MgCl2 and the follow-
ing cycling parameters: 1 cycle at 94°C for 15 minutes fol-
lowed by 40 cycles of amplification for each experiments
using 95°C for 30 seconds, at 58°C for 30 seconds, and at
72°C for 30 seconds. A final cycle was undertaken at 72°C
for 5 minutes, the complete elongation steps and the PCR
products were then resolved on a 2.5% agarose/Tris-borate-
ethylenediaminetetraacetic acid gel.
Site-directed mutagenesis
Site-directed mutagenesis was carried out to test the
effects of altering alter key bases in either the different
putative transcriptional start sites or transcription factor
binding sites, such as Brn-3b site or oestrogen response
element (ERE), in the Brn-3b promoter. This was achieved
using the QuickChange Site-Directed Mutagenesis Kit
(Stratagene, Stockport, Cheshire, UK) and experiments
were carried out in accordance with the manufacturer pro-
tocol. Primers used to mutate the Brn-3 site (located at
-1,324 bp to -1,312 bp from ATG) were forward 5’-
CCCTTCTTCCTTTGATTGTGGCTAATGAAGAAG-
GATCCATCCAGGGG CAGGGTTT-3’ and reverse 5’
AAACCCTGCCCCTGGATGGATCCTTCTTCATTAGC
CACAATCAAAGGAAGAAGGG-3’. Primers used to
mutate ERE (located at -1,263 bp to -1,255 bp from ATG)
were forward 5’-CATATGCGCTGTGTAATTT CTGG
AATTCCCTC TCCCTGTCAGTTG-3’ and reverse 5’-
CAACTGACAGGGAGAGGGAATTCCAGAAAT TAC
ACAGCGCATATG-3’. Primers used to alter the upstream
initiator (located at -1,048 bp to -1,042 bp) were forward 5’
CCAACGCTGGCTTGGGCCGCAACTCTAGATGG-
GAGTTTTCTTTTTC-3’ and reverse 5’-GAAAAA-
GAAACTCCCATCTAGAGTTGCGGCCCAAGCCAGC
GTTGG-3’. To mutate the proximal TATA (located at
-278 bp to -271 bp from ATG), we used the following pri-
mers: forward 5’-GCGGGGAGAGGGGGGTACCCCT
CGCCGG CCGCG-3’, reverse 5’-CGCGGCCGGCGAG
GGGTACCCCCCTCTCCCC GC-3’. To mutate intronic
TATA (located at +293bp to +297 bp from ATG), we
used the following primers: forward 5’-GTCTTCCAA
CCCCACCGGTGGGTACCCCTGCATAATCACCGCT
TA AA-3’ and reverse 5’-TTTAAG CGGTGATTATG-
CAGGGGTACCCACCGGTGGGGTT GGAAGAC-3’.
Consecutive rounds of mutagenesis were performed to gen-
erate double or triple mutants. Restriction analysis, together
with DNA sequencing, confirmed the resulting mutations.
Western blot analysis
Total cellular protein preparation and immunoblotting
were undertaken as previously described [6] with 1 hour
block in phosphate-buffered saline Tween-20, primary
Ab incubation for 1 to 3 hours and secondary Ab incu-
bation for 45 to 60 minutes. Signals were developed
using enhanced chemiluminescence reagent (Amersham,
Buckinghamshire, UK).
Cell culture, transient transfections and reporter assays
MCF-7 breast cancer cells were maintained in Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum, 1% nonessential amino acids
and 1% penicillin/streptomycin. Cells were plated onto
six-well plates (5 × 104 cells/well) 24 hours before trans-
fection with reporter and expression vectors using
FuGENE HD Transfection Reagent (Roche, Welwyn
Garden City, Hertfordshire, UK) or GeneJuice Transfec-
tion Reagent (Merck Biosciences, Nottingham, UK).
Transfection was undertaken according to the manufac-
turer’s protocol. To reduce the activity of endogenous
ER, cells were grown in oestrogen-depleted medium,
that is, phenol red minus DMEM supplemented with
charcoal-stripped FCS [9], for up to 72 hours before
transfection and subsequent analysis. Forty-eight hours
following transfection promoter activity was measured
using the Dual-Luciferase Reporter Assay System (Pro-
mega, Southampton, UK) according to the manufac-
turer’s protocol using a TD 20/20 luminometer (Turner
Designs, Promega, Southampton, UK). Internal control
Renilla luciferase reporter activity was used to control
for variations in transfection efficiency, and values are
expressed as percentages of empty vector control.
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Results
Identification of the Brn-3b promoter
Bioinformatics analysis of 5’ sequences upstream of the
Brn-3b coding sequence using the VISTA Genome
Browser [13,14] revealed regions of high conservation
across different species (Figure 1a). Such sequence
homology often indicates key functions [12], so in silico
analysis was undertaken for regulatory sequences in this
noncoding region. Using BIMAS ProScan software [12],
we identified putative transcription initiation sequences
(for example, TATA or initiator elements) within the
proximal sequences (Figure 1a), which can be indicative
of promoters. Furthermore, analysis of the sequence
using MatInspector Transcription Factor Analysis Tool
software (TransFac, Genomatix) led to the identification
of putative binding sites for transcription factors that
are known to regulate the growth of cancer cells, for
example, estrogen receptor element (ERE), epidermal
growth factor response element (EGRF) and serum
response element (SRE). Because of the high conserva-
tion across species, we examined whether polymorphism
in these sequences might contribute to elevated Brn-3b
expression in breast cancer biopsies by sequencing and
comparing genomic DNA from 15 primary breast biop-
sies (including normal breast and breast cancer biopsies)
with the breast cancer cell lines HB4a and MCF-7. No
significant polymorphisms were observed, except in
microsatellite sequences (data not shown), suggesting
that the increased Brn-3b mRNA observed in breast
tumours might result from activation of its promoter by
upstream growth effectors and/or signalling pathways
that stimulate gene transcription.
Cloning of promoter and mapping transcription start site
To identify factors that stimulate Brn-3b promoter activ-
ity and therefore gene expression in breast cancer cells,
the BSX reporter construct, containing the putative Brn-
3b promoter and regulatory sequences cloned into pGL2
basic reporter vector (see Materials and methods, and
Figure 1b) was used in transfection studies. Figure 1c
shows high basal activity from the Brn-3b promoter con-
struct compared with empty pGL empty vector control,
thereby confirming that these sequences were sufficient
to promote reporter gene expression. The BSXEIE con-
struct containing additional sequences, including the
intron region, give rise to similar results (not shown).
To identify sites from which transcription may be
initiated on this promoter, an in vivo ChIP assay was
undertaken using an antibody to the TBP component of
the basal transcriptional complex [13]. Primers were
designed to amplify regions that flanked putative tran-
scription start sites, as shown in Figure 1d (position in
reference to first ATG), and referred to as upstream
initiator sequence (at position -1048 to -1042) or
proximal TATA-like sequence (located at -278 to -272).
The primers used to amplify an intronic region with
TA-like elements were also tested because this region
was found to have an alternative promoter in the related
Brn-3a gene, which has a genomic arrangement similar
to that of Brn-3b. The primers for sequences in exon 2
were used as negative controls.
Figure 1e shows the PCR products obtained following
amplification of a-TBP ChIP DNA using primers for
different putative start sites in the promoter. Figure 1e
(lane B) shows that primers flanking the putative proxi-
mal TATA site at -278 (-278TATA) produced a strong
band that was not seen when these primers were used
to amplify control ChIP DNA (secondary Ab). This pro-
duct was comparable to the positive control PCR pro-
duct obtained using primers that amplified the known
start site in the GAPDH gene (Figure 1e, lane E),
suggesting significant TBP binding to this proximal
TATA-containing region of the promoter. In contrast,
amplification of sequences spanning the putative upstream
initiator element (Figure 1e, lane A) or intronic regions
(Figure 1e, lane C) gave rise to faint bands. This may result
either from weak binding of TBP to these regions or from
variability in shear size of ChIP DNA. No bands were
seen with primers amplifying exon 2 (negative control)
(Figure 1e, lane D), indicating the specificity of the assay.
The data therefore suggest significant binding of TBP to
proximal TATA and possibly weak binding to initiator ele-
ments and sequences within the intron.
To confirm which of these sites was required for tran-
scription initiation, site-directed mutagenesis was used
to alter bases at the proximal -278TATA site, the
upstream site (-1,042) or within the intronic TA
sequences either alone or in different combinations
(Figure 2a). Mutated constructs were used for similar
transfection assays, and the results, shown in Figure 2b,
demonstrate that mutation of -278TATA alone
(Δ-278TATA column) resulted in significantly reduced
promoter activity (by 70% to 80%) compared with the
WT promoter (set at 100% - Figure 2a, right, row 1).
Furthermore, when proximal -278TATA was mutated in
any combination (with initiator-like elements at -1,042
or intronic TA), a similar loss of promoter activity was
observed (Figure 2a, right, rows 7 and 9). However,
mutation of upstream initiator-like elements (-1,048 to
-1,042) alone (Figure 2a, right, row 2) or intronic
TATA-like elements alone or in combination (Figure 2a,
right, rows 4 to 6) did not reduce promoter activity if
-278TATA was intact. These results suggest that the
proximal TATA element (-278 from ATG) is essential
for the formation of basal promoter complex required
to drive expression from the Brn-3b promoter and
hence will mark the vicinity of the transcriptional start
site. The intronic TA and distal initiator element did
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not appear to be sufficient or required for transcrip-
tional initiation, independently of this proximal TATA,
in breast cancer cells.
Since -278TATA is necessary for transcriptional activ-
ity, we next tested whether altering this element was
sufficient to reduce Brn-3b protein expression in these
cells. For the studies, we used the BSXEIE constructs, in
which the WT or mutant Brn-3b promoter (in which
residues in -278TATA were altered in the otherwise
intact promoter) was cloned upstream of its own coding
sequence (comprising EIE) and therefore drives its own
expression. Following transfection, protein extracts from
cells transfected with WT or mutated -278TATA were
used for immunoblotting to measure exogenous Brn-3b
protein produced from the transfected BSXEIE construct
compared with baseline expression (in empty vector
transfected cells). Figure 2b (WT column) shows
increased Brn-3b protein levels in cells expressing the
WT construct (with intact -278TATA driving Brn-3b
gene expression) compared with basal levels in untrans-
fected control cells ("No Reporter” column). This was
more evident for the longer Brn-3b(l) isoform because
basal levels expressed in control cells are much lower
compared with the shorter Brn-3b(s) isoform. However,
Figure 2 Analysing the transcription start sites of Brn-3b promoter. (a) Analysis of Brn-3b promoter (BSX) activity following the mutation of
key sites to identify the transcriptional start site. Wild-type (WT) promoter in row 1 (right) is represented as 100%, and all mutations are
expressed as percentages of the WT promoter. Schematic shows positions of mutations at key sites (indicated by x, left), for example, upstream
initiator alone (row 2, right) or in combination with other sites (rows 7 to 9, right). The proximal -278TATA mutation is shown alone (row 3, right)
or in combination (rows 7 and 9, right). The effects of mutation of different intronic TA alone (rows 4 to 6, right) or in combination (rows 8 to
10, right) are also shown. Values are equalised to internal control (Renilla luciferase), and the results represent data from three independent
experiments expressed as means + SD. * is used to show statistical significance between different mutant promoter constructs and wild-type
constructs. (b) Western blot analysis of Brn-3b protein expression in cellular extracts prepared from MCF7 cells transfected with BSXE1E
expression constructs in which Brn-3b promoter drives expression of the Brn-3b gene. WT promoter activity is shown in left column. Middle
column (Δ-278TATA shows the reduction in Brn-3b protein from expression constructs containing a mutation within the proximal -278TATA
promoter of an otherwise, intact construct. Right column shows untransfected control cells with no reporter and therefore represents levels of
endogenous Brn-3b protein in these cells.
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mutation of -278TATA (in the otherwise intact con-
struct) resulted in loss of this induction of Brn-3b pro-
tein (Δ-278TATA column) since levels were similar to
endogenous expression in control cells. On the basis of
the results of these different studies, we concluded that
the proximal TATA located at position -278 from ATG
(-278TATA) marks the transcription start site for Brn-
3b transcription breast cancer cells.
Brn-3b promoter is stimulated by NGF and EGF via the
MAPK pathway
Since Brn-3b mRNA is increased in breast cancers, we
next tested whether this promoter is regulated by
growth factors that alter proliferation of these cancer
cells. Therefore, MCF7 cells, transfected with the BSX
promoter, were treated with known growth regulators
including cyclic AMP (cAMP); epidermal growth factor
(EGF); nerve growth factor (NGF) and insulin-like
growth factors (IGF-1) [14-17]. Transforming growth
factor (TGFb), which is an inhibitor of cell growth[18],
was also tested. Figure 3a shows stimulation of Brn-3b
promoter activity by NGF (300 ng/ml) and EGF (50 ng/
ml) whereas IGF-I (1-100 nM), TGFb (0.5-20 ng/ml)
and cyclic AMP (1 uM) had no effect on its activity in
these cells. Both NGF and EGF could stimulate this
promoter at a range of different concentrations tested
(100-500 ng/ml for NGF and 1-100 ng/ml for EGF)
(data not shown).
Analysis of the Brn-3b promoter using MatInspector
TransFac Analysis Tool software identified multiple
transcription factor binding sites for transcription fac-
tors stimulated by these growth factors, for example,
EGR and NGF induced protein C. Therefore, we tested
whether this region of the promoter was necessary for
promoter stimulation by specific growth factors. Because
of the presence of multiple sites in this region of the
promoter, it was necessary to generate deletion con-
structs instead of mutating individual sites. Therefore,
Sma1 restriction enzyme sites were used to delete a
region of the promoter containing six EGFR and SRE
sites by restriction enzyme digestion and religation. The
resultant deletion promoter construct generated follow-
ing Sma1/Sma1 digests (SS), which was designated
BS-SS (shown in Figure 3b), was used in similar cotrans-
fection assays, with or without NGF or EGF. Figure 3c
shows that the BS-SS deletion reporter construct was no
longer stimulated by NGF or EGF, as seen in the WT
promoter. Although basal activity was slightly lower
than that of the WT promoter, this did not account for
the loss of inducibility by NGF and EGF, suggesting that
Figure 3 Analysing the effect of growth factors on Brn-3b promoter activity. (a) Brn-3b promoter (BSX) activity was measured following
transfection of the reporter construct into MCF-7 cells and treatment with different growth factors. Values were equalised with internal control
and Renilla luciferase activity and expressed as a percentage of promoter only (set at 100%). The data shown represent means ± SD from at
least three independent experiments. NGF, nerve growth factor; EGF, epidermal growth factor; IGF, insulin-like growth factor; TGF, transforming
growth factor; cAMP, cyclic adenosine monophosphate. (b) Schematic showing the position of growth factor response element (EGRF) and
serum response element (SRE) sites in the Brn-3b promoter. The location of two Sma1 restriction enzyme sites, which were used to generate the
deletion (Sma1/Sma1) construct, BS-SS, is shown in relation to the DNA binding sites. The resultant truncated promoter is represented
schematically below. (c) Luciferase activity of intact (BS) promoter (control) or Sma1/Sma1 deletion promoter (BS-SS) is shown following
transfection into MCF-7 cells. Grey bars represent WT promoter activity either alone or following treatment with NGF or EGF, whereas stippled
bars show the activity of the Sma1/Sma1 deletion construct with or without growth factors. Values represent means ± SE of three independent
experiments.
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key DNA binding sites present in this region are essen-
tial for increasing promoter activity in breast cancer
cells.
NGF and EGF act as ligands, which, when bound to
specific receptors, activate signalling pathways that alter
downstream transcription factors, which in turn modu-
late downstream gene expression [16,19]. To identify
pathways that modify promoter activity, cells transfected
with the Brn-3b reporter construct were treated with
pharmacological inhibitors or activators of key signalling
pathways. Figure 4a shows that PD98059, an inhibitor of
the p42/p44 MAPK pathway, strongly and specifically
repressed endogenous Brn-3b promoter activity, whereas
inhibitors of other pathways, for example, SB203580
(p38 kinase inhibitor), Genistein (tyrosine kinase
inhibitor) or Wortmannin (PI3K inhibitor), had no effect
on promoter activity. Furthermore, PD98059 blocked
activation by NGF and EGF, suggesting that these
growth factors stimulate Brn-3b promoter activity by
signalling through the p42/p44 MAPK pathway. Inter-
estingly, strong induction of promoter activity by PDBu,
a potent activator of PKC (Figure 4b) was also inhibited
by PD98059, suggesting an important role for the p42/
p44 MAPK signalling pathway in controlling Brn-3b
promoter activity in breast cancer cells through different
upstream activators.
To confirm the requirement for the p42/p44 MAPK
pathway in stimulating this promoter, we overexpressed
WT MEK1 (an upstream activator of p42/p44 MAPK)
or dnMEK1 with the Brn-3b reporter construct using
Figure 4 Brn-3b promoter is activated via the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK)
pathway in breast cancer cells. (a) Brn-3b promoter activity is shown following treatment of transfected cells with inhibitors of different
signalling pathways (as indicated), in absence or presence of NGF or EGF. Values have been adjusted using internal Renilla luciferase control and
represent means ± SD of at least three independent experiments. (b) Increase in Brn-3b promoter activity following treatment of transfected
cells with the protein kinase C analogue phorbol 12,13-dibutyrate in the absence or presence of the ERK inhibitor, PD98059. Values represent
relative luciferase activity after adjusting for Renilla internal control. (c) Brn-3b promoter activity is shown following cotransfection with either
dominant-negative mitogen-activated protein kinase kinase (dnMEK) or WT MEK compared with activity in the presence of the ERK inhibitor
PD98059. Values represent relative luciferase activity after adjusting for Renilla internal control.
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cotransfection protocols. Figure 4c shows that increasing
WT MEK1 could stimulate endogenous promoter activ-
ity, whereas the dnMEK1 construct reduced basal pro-
moter activity to levels seen with PD98059 treatment.
Thus, Brn-3b promoter activity can be inhibited by
blocking the MAPK/extracellular signal-regulated kinase
(ERK) pathway by using either pharmacological inhibi-
tors or dnMEK, thereby identifying the MAPK/ERK
pathway as a pivotal regulator of Brn-3b expression in
breast cancer cells.
Activation of Brn-3b promoter by the hormone 17b-
estradiol occurs via ERa but not ERb
The hormone oestrogen plays a critical role in the initia-
tion and progression of many breast cancers because
breast epithelial cells are highly responsive to its prolif-
erative effects. Therefore, we tested whether active oes-
trogen (17b-estradiol) could stimulate Brn-3b promoter
activity using MCF-7 cells sensitized to estradiol by
growth in stripped-serum, phenol-red less DMEM [9].
Cells transfected with the Brn-3b promoter construct
were either untreated or treated with different concen-
trations of 17b-estradiol. Figure 5a shows that 17b-estra-
diol significantly increased promoter activity compared
with untreated cells, suggesting that this hormone can
stimulate Brn-3b transcription in breast cancer cells,
thereby contributing to downstream oestrogenic growth
effects.
Estradiol can act through one of two receptors: ERa
or ERb. Of these, increased ERa is implicated in the
etiology of breast cancers and is often targeted for treat-
ment. We therefore tested the effects of coexpressing
either ERa or ERb on Brn-3b promoter activity.
Figure 5b shows that the promoter was strongly stimu-
lated by ERa, whereas ERb did not alter its activity, sug-
gesting that the effects of oestrogen in breast cancer
cells are likely to be mediated via ERa. As expected, the
addition of the ER antagonist tamoxifen prevented acti-
vation of the Brn-3b promoter by oestrogen (Figure 5c),
thus confirming that this receptor is required for stimu-
lation of Brn-3b promoter activity in MCF-7 cells. This
finding was further supported by studies carried out in
ER-negative Cos-7 cells, which showed that estradiol did
not activate the Brn-3b promoter unless exogenous ER
was introduced following transfection (Figure 5d). These
results suggest that ERa is necessary to mediate the
effects of oestrogens in MCF-7 breast cancer cells but
can also act independently of oestrogen to increase Brn-
3b transcription.
Autoregulation by Brn-3b and cooperation with ERa also
increases promoter activity
TRANSFAC software analysis revealed binding sites for
Brn-3 proteins, suggesting that Brn-3b and/or a related
family member, Brn-3a, may also regulate promoter
activity. A putative ERE site was identified within proxi-
mity to this site (Figure 6a), and since previous studies
demonstrated physical interaction between Brn-3b and
ERa that could stimulate transcription of ERE-contain-
ing target genes, we tested whether Brn-3b could regu-
late its own promoter activity and cooperate with ERa
to increase its own expression.
Figure 6b shows that Brn-3b could weakly transacti-
vate its own promoter, whereas the related Brn-3a pro-
tein had no effect on promoter activity in these cells.
Although ERa alone stimulated promoter activity, coex-
pression of this receptor with Brn-3b resulted in more
significant increases. ERb did not affect promoter activ-
ity with or without Brn-3b, suggesting that a specific
and unique cooperation occurs between ERa and Brn-
3b to stimulate the Brn-3b promoter in breast cancer
cells. Studies carried out in sensitised MCF7 cells grown
in “phenol red less” DMEM, containing stripped serum,
to deplete oestrogenic activity, shows that exogenous
(transfected) ERa could to stimulate Brn-3b promoter
in the absence or presence of estradiol and also coop-
erated with Brn-3b to further enhance promoter activity
(Figure 6c). These results suggest that stimulation of
Brn-3b promoter by ERa can occur independently of
estradiol stimulation. We also tested whether increased
promoter activation caused by the coexpression of Brn-
3b and ERa could also result in enhanced protein
expression. For this study, we used the modified
BSXE1E construct (Figure 6d), in which the Brn-3b pro-
moter, (containing Brn-3 and ERE elements), drives
expression of its own coding sequence. This BSXEIE
construct was cotransfected with Brn-3b or ERa expres-
sion vectors, alone or together, into MCF-7 cells. Pro-
teins extracted from transfected cells after 48 hours
were used for immunoblotting to detect Brn-3b protein.
Figure 6e shows that transfected cells coexpressing exo-
genous Brn-3b and ERa produced higher levels of Brn-
3b protein than basal levels in control cells (column 1)
or in cells transfected with Brn-3b alone (column 3),
where the band represent exogenous as well as endo-
genous Brn-3b proteins. Thus, coexpression of Brn-3b
with ERa at ratios of 1:1 and 1:2 (Brn-3b:ERa) resulted
in increased Brn-3b protein, but further increases in
ERa (1:4 ratio) resulted in reduced protein levels, which
is suggestive of squelching. To demonstrate this
squelching effect, we needed to show reduction of Brn-
3b protein expression at the higher ratio and this was
achieved by reducing exposure times. However, under
those conditions, the increases in endogenous Brn-3b fol-
lowing transfection with ERa only were not evident in
Figure 6e but can be seen in Figure 6f. Thus, transfecting
increasing amounts of ERa expression vector (0.5 -2.0
μg) resulted in increased ERa protein (Figure 6f - top
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immunoblot), and correlated with enhanced expression
of endogenous Brn-3b (lower immunoblot). Therefore,
the stimulatory effects of the oestrogen receptor can
directly increase transcription from Brn-3b gene promo-
ter but also cooperates with Brn-3b to further enhance
expression. However this cooperativity is influenced by
the ratio of Brn-3b to ERa in cells.
Mutation of Brn-3 binding sites leads to loss of regulation
by ERa
The BS-SS deletion construct (described in Figure 3b),
lacked the Brn-3 and ERE binding sites. Therefore, we
analysed the effects of Brn-3b, with or without ERa, on
promoter activity and showed loss of inducibility by
Brn-3b and ERa (Figure 7a), suggesting that these sites
are important for promoter transactivation. We next
tested whether these sites were essential for promoter
activation, by mutating the Brn-3 consensus sequence
(Brn3 mutation in Figure 7b) and ERE (ERE mutation in
Figure 7c), either alone or together (Brn3-ERE mutation
in Figure 7c), using site-directed mutagenesis. Mutant
and WT promoter was then used to test the effects of
Brn-3b and ER on promoter on activity following
cotransfection studies. Figure 7b (black bars) shows the
Figure 5 Brn-3b promoter activity is strongly stimulated by 17b-estradiol via activation of oestrogen receptor a (ERa). (a) Brn-3b
promoter activity following treatment of transfected MCF-7 cells with different concentration of 17b-estradiol. Values have been adjusted with
internal control, Renilla luciferase and represent means ± SD of three independent experiments ***indicate statistical significance of p < 0.0001
compared with control. (b) Effect of different oestrogen receptors, ERa or ERb on Brn-3b (BSX) promoter activity are shown after cotransfection
into sensitised MCF-7 cells (grown in stripped serum medium for 48 hours). Promoter activity is adjusted to internal Renilla control and
expressed as percentage of levels seen with empty vector only (set at 100%). Values represent data from three independent experiments,
expressed as means ± SD. (c) Activation of Brn-3b promoter by ERa can be blocked by the receptor antagonist tamoxifen. Promoter activity is
shown after cotransfection of Brn-3b promoter with ERa into sensitised MCF-7 cells (grown in oestrogen-depleted medium for 48 hours) in the
presence of 1 μM 4 hydroxy tamoxifen (TAM) compared with untreated control. Promoter activity is adjusted to internal Renilla control and
expressed as percentages of levels seen with untreated controls (set at 100%). (d) Brn-3b promoter activity in ER-negative Cos-7 cells treated
with estradiol and either transfected ERa or control vector. Data shows luciferase activity in cells transfection of Brn-3b promoter and treatment
with either vehicle (-E2) or 10 nM estradiol (+E2) in the absence or presence of ERa.
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expected cooperation between Brn-3b and ERa on the
WT promoter, whereas mutation of the Brn-3 site (open
bars) resulted in loss of induction by Brn-3b but also
prevented activation by ERa or cooperative stimulation
when ERa is co-expressed with Brn-3b. Mutation of the
putative ERE did not affect promoter activity (Figure 7c,
light grey bars) but loss of ERE and the adjacent Brn-3
site, in double mutants (Figure 7c, dark grey bars) abol-
ished stimulation by ERa and cooperativity between
Brn-3b and ER. These results showing that the stimula-
tory effects of ERa is not dependent on binding to ERE
if the Brn-3b binding site is intact suggest that protein-
protein interaction with Brn-3b might facilitate recruit-
ment of ERa to the promoter. Therefore, ER-mediated
Figure 6 Cooperation between Brn-3b and ER can stimulate promoter activity. (a) Schematic diagram showing position of Brn-3
consensus binding sites and oestrogen response element (ERE) site relative to the proximal -278TATA, (now designated +1). (b) Promoter
activity following cotransfection of the BSX reporter construct with Brn-3b, Brn-3a, ERa or ERb alone or in different combinations into MCF-7
cells. Values have been equalised with internal Renilla control [renilla reporter gene driven by minimal tyrosine kinase (TK) promoter] and
represent means ± SD of three independent experiments. (c) Brn-3b promoter activity when coexpressed with Brn-3b and ERa, alone or
together, in cells grown in oestrogen-depleted medium and either untreated or treated with estradiol, after transfection. Grey bars show
inducibility in the absence of estradiol, and black bars demonstrate the effects of adding estradiol after transfection with the constructs
described. (d) Schematic showing the modified expression construct, BSXE1E, in which the Brn-3b promoter drives expression of the Brn-3b
gene upstream of luciferase reporter (L). (e) Immunoblot showing changes in Brn-3b protein produced from the BSXE1E expression construct
when cotransfected with Brn-3b or ERa alone or in combination (at different ratios of Brn-3b:ER, 1:1 to 1:4). Actin immunoblot was used to
indicate variation in protein loading. To demonstrate that Brn-3b protein levels was dependent on the ratio of Brn-3b to ER, shorter exposure
times and therefore smaller increases in Brn-3b expression are not evident when ER only is expressed. (f) Immunoblot to show increases in ER
protein following transfection with expression constructs (top immunoblot) and a corresponding changes in endogenous Brn-3b protein that
were dependent on concentrations of ERa (middle immunoblot). GAPDH immunoblot is included to show variation in protein loading.
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activation of this promoter is not solely dependent on
the ERE site at this position.
Since the Brn-3 site was shown to be important for
activation of this promoter, chromatin immunoprecipi-
tation (ChIP) assay was utilised to show that Brn-3b
does indeed bind to this site on the promoter in vivo in
intact cells. Figure 7d shows the PCR product resulting
from amplification of promoter sequences containing
the Brn-3b site when using Brn-3b ChIP DNA obtained
following Chip with Brn-3b antibody from MCF-7 cells
overexpressing Brn-3b. PCR primers were used to
amplify the promoter region containing the putative
Brn-3b site. Input (left column) indicates amplification
of chromatin from cells prior to immunoprecipitation,
whereas ChIP DNA using Brn-3b Ab (right column)
gave rise to significant amplification products, which
was not seen following PCR using ChIP DNA with con-
trol Ab (middle column). These results therefore con-
firm that Brn-3b is indeed bound to this region of its
own promoter in vivo in intact cells.
Discussion
The mechanisms underlying the development and pro-
gression of breast cancer are not fully understood, and
this is particularly challenging because of its diverse
etiologies [20]. However, it is clear that changes in gene
expression are essential to drive different processes that
occur during tumourigenesis [21]. Transcription factors
control gene expression by binding to specific DNA
sequences in gene promoters and often regulate multiple
Figure 7 Mutation of Brn-3 site reduces the inducibility of promoter by ERa and also abolishes cooperativity. (a) Testing effects of ERa
with or without Brn-3b on activity of deletion promoter, BS-SS, in which putative binding site for Brn-3b and ERa are lost. Reporter gene activity
was adjusted using internal control, Renilla luciferase. Values are shown relative to BS promoter activity in the presence of control empty vector,
LTR, set at 100%. Effects of ERa or Brn-3b, alone or together on the intact BS promoter or deletion (BS-SS) promoter are compared (b) Reporter
gene activity following cotransfection of Brn-3b or ER (alone or together) with WT or mutant Brn-3b reporter construct in which Brn-3b site is
mutated. Values have been adjusted for internal Renilla luciferase control and are expressed as percentages of activity in empty vector
transfected cells (set at 100%) for the respective promoters. Results represent means ± SD from three independent experiments. (c) Similar
reporter assays were used to show changes in activity of Brn-3b promoter containing mutation of ERE alone (ERE mutant) or double-mutant
lacking both sites (Brn-3/ERE mutant) when coexpressed with Brn-3b +/- ERa. The data represent means ± SD of three independent
experiments. (d) Representative PCR product obtained using ChIP DNA (immunoprecipitated with Brn-3b antibody) and primers to amplify and
promoter region containing the putative Brn-3b binding site. Input column represents PCR amplification using one-tenth of isolated DNA before
ChIP. Middle column (-ve Ab) shows product following ChIP assay with negative control a-rabbit Ab only). Right column (Brn-3b Ab) shows
product resulting from ChIP assay using Brn-3b Ab.
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target genes. Because of this ability to control different
target genes, deregulation of transcription factors can
drive events associated with the initiation and progres-
sion of diseases such as cancer [22]. Previous studies
have shown that the Brn-3b transcription factor is ele-
vated in >60% of primary breast cancers [1], and when
increased, it significantly enhances proliferation and
anchorage-independent growth in vitro and tumour
growth in vivo [2,3]. Elevated Brn-3b also confers resis-
tance to growth-inhibitory stimuli and increases the
migratory potential of cancer cells [2], suggesting that
this transcription factor acts through complex mechan-
isms in cancer cells. More recent studies have shown
increases in Brn-3b in drug-resistant, migratory breast
cancer cells (unpublished data, R. Fujita and V. Budhram-
Mahadeo). The Brn-3b can give rise to such diverse effects
because it regulates different subsets of target genes that
control distinct aspects of cellular growth and behavior.
For example, Brn-3b might contribute to cellular prolifera-
tion by transactivating the promoters of cell cycle regula-
tors, CDK4 [4] and cyclin D1 [5] whilst repressing the
tumour suppressor, BRCA1 [6]. However, its effects on
drug resistance and migration are likely to be associated
with the ability of Brn-3b to regulate other genes, for
example, to transactivate Hsp27 [7] whilst repressing adhe-
sion molecules, for example, g-catenin [8].
Interestingly, reducing Brn-3b was sufficient to change
gene expression and reverse many growth effects [1].
Therefore, Brn-3b can act as a master regulator whose
expression profoundly alters the growth of cancer cells.
In this regard, Brn-3b might represent an important
therapeutic target whose reduction could alter the
expression of multiple downstream target genes and
thereby reverse their effects on cancer cells. However, to
identify strategies for reducing Brn-3b in these cells, we
must understand the mechanisms that lead to its
increased expression in breast cancer cells.
In this study, we utilised bioinformatics analysis to
identify the putative Brn-3b promoter and cloned this
regulatory region into a reporter construct for further
experimental analysis. By using ChIP assays and site-
directed mutagenesis, we identified a key TATA tran-
scriptional start site located at ~278 bp from ATG,
which is primarily associated with the expression of
Brn-3b mRNA in breast cancer cells. Although the
upstream initiation site and TA-like elements in the
intronic sequence were weakly immunoprecipitated by
TBP Ab, these do not appear to be candidates for tran-
scriptional start sites, since the mutation of any or all
intronic TA sequences or upstream sequences did not
reduce promoter activity, if the start site at -278TATA
was intact. This is interesting because an intronic pro-
moter is thought to be important to drive isoform-speci-
fic expression of the related Brn-3a gene, which has a
genomic arrangement similar to that of Brn-3b. How-
ever, our results suggest that Brn-3b promoter activity
in breast cancer cells is driven primarily from the proxi-
mal -278TATA site, which is now used to define the
transcription start site from this promoter.
Further analysis showed that the Brn-3b promoter can
be stimulated by specific growth factors, NGF and EGF,
but not by IGF-1, cAMP or TGFb, and these stimula-
tory effects require a region of promoter that contains
multiple EGFR and SRE sites. The ability of growth fac-
tors such as NGF to increase transcription from the
Brn-3b promoter is significant because NGF is known
to enhance the growth and drive proliferation of breast
cancer cells but not of normal breast epithelial cells.
Moreover, blocking NGF can inhibit tumour growth
and metastasis [16,23], suggesting a key role for NGF in
controlling the growth of cancer but not of normal cells.
NGF is produced in an autocrine manner by breast can-
cer cells, and its mitogenic effects in these cells are
mediated through the p42/p44 MAPK signalling path-
way, since these effects can be blocked by the pharma-
cological inhibitor PD98059, which targets MEK1 in this
pathway [24]. In this study, we showed that stimulation
of the Brn-3b promoter by NGF is blocked by PD98059,
suggesting that the mitogenic effects of NGF in breast
cancer cells may result in part from its ability to
increase the expression of regulators such as Brn-3b.
The PKC analogue PDBu is also a potent activator of
the Brn-3b promoter, and its effects can also be blocked
by PD98059, suggesting that this activator converges on
the p42/p44 MAPK/ERK1 pathway to stimulate Brn-3b
promoter activity. Dominant negative (Dn) MEK also
blocked endogenous Brn-3b promoter activity, in a man-
ner that is similar to the ERK1 inhibitor, PD98059. Thus
it would appear that the p42/p44 MAPK/ERK pathway
is pivotal for activating the Brn-3b promoter and hence
expression in breast cancer cells.
In addition to stimulation by growth factors, the Brn-
3b promoter is strongly activated by the hormone estra-
diol, which regulates the growth and proliferation of
normal breast epithelium as well as breast cancer cells
and is important in the etiology of breast cancer [25].
Oestrogens can regulate gene transcription by acting
through one of two receptors: ERa or ERb. Our results
show that overexpression of ERa but not ERb could
strongly stimulate Brn-3b promoter activity. ERa is par-
ticularly relevant for the development and progression
of breast cancers because it is overexpressed in a signifi-
cant proportion of breast cancers (> 60%). Furthermore,
ER-positive breast cancers are often treated using recep-
tor antagonists, for example, tamoxifen, as a first line of
therapy aimed at blocking ER-mediated proliferative
effects [26]. Therefore, the ability of ERa to stimulate
Brn-3b suggests that the proliferative effects of high ER
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levels may be associated with the ability of ERa to trans-
activate other regulators, such as Brn-3b, which in turn
can modulate genes associated with growth in these
cancer cells either alone or by cooperating with ERa.
The complexity underlying the regulation of the Brn-
3b promoter is increased by autoregulation, whereby
Brn-3b can weakly stimulate its own expression by bind-
ing to recognition sequences present in its promoter.
However, cooperation between Brn-3b and ERa could
further enhance promoter activity. Such cooperation
between Brn-3b and ERa to increase gene expression
was previously observed on other ERE-containing target
promoters, for example, HSP27, where Brn-3b stimu-
lates expression directly by binding to specific sites in
the promoter or indirectly by interacting and cooperat-
ing with ER to maximally activate this promoter [7].
This ability of Brn-3b to cooperate with ERa to enhance
gene expression [9], including its own, is clearly relevant
to breast cancer because ER-expressing tumours that
are responsive to estradiol will stimulate Brn-3b, which
can cooperate with ERa to further increase its own
expression. Interestingly, mutation of the putative ERE
did not prevent ER-mediated promoter activation when
coexpressed with Brn-3b, but mutation of the nearby
Brn-3 site abolished activation by ER and its cooperation
with Brn-3b. This indicates that ERa could stimulate
Brn-3b promoter even if it is not bound to ERE, possibly
because interaction with Brn-3b allows recruitment of
ER to the promoter. Autoregulation of Brn-3b transcrip-
tion, either alone or by cooperating with ER, is likely to
increase Brn-3b protein expression and subsequently, its
target genes in these cells.
Although stimulation of Brn-3b promoter activity by
the hormone oestrogen via ERa is likely to act indepen-
dently and possibly, in parallel with growth factor-
mediated promoter activation via the p42/p44 MAPK
signalling, there is also significant “cross-talk” between
these pathways in breast cancer cells. Thus, estradiol
primarily acts through its receptor, ERa, in breast can-
cer cells, but it can also indirectly stimulate tyrosine
kinase receptors, which are also relevant to breast can-
cer cells. Similarly, transcriptional activity of oestrogen
receptor, ERa, is also modulated by p42/p44 MAPK
pathway stimulation [27]. Evidence for cross-talk
between NGF or EGF and the estradiol pathways has
also been demonstrated [28], and in this regard, the
anti-oestrogenic drug tamoxifen can inhibit proliferation
by EGF or NGF on MCF-7 breast cancer cells [29].
Therefore, diverse pathways, which are stimulated by
either hormone or growth factor may act in parallel or
converge to stimulate Brn-3b promoter activity and
hence increase its expression in breast cancer cells. Evi-
dence for autoregulation by Brn-3b and cooperation
with ERa to increase drive its own promoter activity,
would suggest that under such circumstances, this feed-
back loop will maintain high Brn-3b expression. When
elevated, Brn-3b is likely to alter the expression of mul-
tiple downstream target genes, thereby affecting growth
and behaviour in these cancer cells.
Conclusions
Elevated Brn-3b profoundly enhances tumour growth
and confers drug resistance in breast cancer cells, so it
is important to identify which factors increase its
expression in these cells. In the present studies, we have
cloned and analysed the Brn-3b promoter. Furthermore,
we have identified key pathways that converge on its
promoter to increase activity and hence gene and pro-
tein expression in breast cancer cells. Thus, the hor-
mone oestrogen and the growth factors NGF and EGF
stimulate the activity of the Brn-3b promoter and subse-
quently, Brn-3b mRNA and protein expression, suggest-
ing that induction of Brn-3b by such factors will be
important in changing the fate of these cells. Increased
Brn-3b expression via growth factors such as NGF and
EGF or the hormone, estradiol, which are implicated in
enhancing the growth of breast cancer cells, are likely to
be are propagated by autoregulation. This will lead to
changes in multiple Brn-3b target genes which control
the growth and behaviour of cancer cells. By elucidating
the mechanisms through which regulators such as Brn-
3b are increased in cancer cells, we will increase the
understanding of how changes are brought about during
the development and progression of this disease, and we
may also be able to identify strategies to reduce its
expression and reverse its effects in breast cancer cells.
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